Dr. Sequist Discusses Combination Regimens in EGFR+ NSCLC

Lecia V. Sequist, MD
Published: Tuesday, Feb 13, 2018



Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non–small cell lung cancer (NCSLC).

Sequist says that one of the unique benefits of the third-generation agents having fewer adverse events is that there are more possibilities for combination regimens. In the past, frequently used agents such as erlotinib (Tarceva) or afatinib (Gilotrif) in combination with other therapies caused high rates of toxicities.

Moving forward, Sequist says that she is looking out for new trials with third-generation agents. There is potential in combinations of 2 EGFR-targeting drugs, or combinations with MET, JAK, or BRAF inhibitors. These combination trials will be done in the resistance setting or possibly the frontline setting, Sequist adds.  


Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non–small cell lung cancer (NCSLC).

Sequist says that one of the unique benefits of the third-generation agents having fewer adverse events is that there are more possibilities for combination regimens. In the past, frequently used agents such as erlotinib (Tarceva) or afatinib (Gilotrif) in combination with other therapies caused high rates of toxicities.

Moving forward, Sequist says that she is looking out for new trials with third-generation agents. There is potential in combinations of 2 EGFR-targeting drugs, or combinations with MET, JAK, or BRAF inhibitors. These combination trials will be done in the resistance setting or possibly the frontline setting, Sequist adds.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x